Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2014
06/04/2014CN102464667B Five-membered heterocycle pyrimidine compounds, preparation method and application thereof
06/04/2014CN102453089B Preparation and application of recombinant consensus interferon mutant polyethylene glycol conjugate
06/04/2014CN102448987B Anti-VEGF monoclonal antibody and pharmaceutical composition comprising said antibody
06/04/2014CN102414211B 3-([1,2,3]triazole-4-yl)-pyrrolo[2,3-b]pyridine derivates
06/04/2014CN102413831B Substituted imidazoquinoxalines
06/04/2014CN102369187B N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators
06/04/2014CN102355897B Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
06/04/2014CN102311493B Peptide inhibiting telomerase activity, its preparation method and application
06/04/2014CN102258712B Chinese medicinal composition for adjuvant therapy of tumor and preparation method
06/04/2014CN102249958B Inhibitor of benzoylammonia histone deacetylase
06/04/2014CN102210653B Burdock aglycone microemulsion
06/04/2014CN102178646B Stable Tegafur injection and preparation method thereof
06/04/2014CN102167740B Fully human anti-VEGF (Vascular Endothelial Growth Factor) monoclonal antibody and preparation method as well as application thereof
06/04/2014CN102159541B Anticancer oral formulation
06/04/2014CN102124005B Cmet inhibitors
06/04/2014CN102038650B G.japonicum mycelium polysaccharide refined substance freeze-dried powder injection and preparation method thereof
06/04/2014CN101891635B Crystal forms of citric acid nolvadex and preparation method of crystal form A
06/04/2014CN101889015B Pyrimidine substituted purine derivatives
06/04/2014CN101862345B Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
06/04/2014CN101861313B Phenyl amino pyrimidine compounds and uses thereof
06/04/2014CN101687866B Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
06/04/2014CN101613409B PDGFR-alpha antibody
06/04/2014CN101405019B Medicine for treating tumor and use thereof
06/04/2014CN101379058B Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
06/03/2014US8742119 Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
06/03/2014US8741970 Composition and method for the enhancement of the efficacy of drugs
06/03/2014US8741947 Biologically active macrolides, compositions, and uses thereof
06/03/2014US8741912 Deazapurines useful as inhibitors of Janus kinases
06/03/2014US8741897 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
06/03/2014US8741889 Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor
06/03/2014US8741843 Compositions and methods for inducing angiogenesis
06/03/2014US8741642 Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects
06/03/2014US8741576 Heteroclitic analogs and related methods
06/03/2014US8741351 Microspheres for active embolization
06/03/2014US8741308 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
06/03/2014US8741306 Kidney specific tumor vaccine directed against kidney tumor antigen G-250
06/03/2014US8741303 Immunogenic LHRH compositions and methods relating thereto
06/03/2014US8741259 Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists
06/03/2014CA2678255C Inhibitors of akt activity
06/03/2014CA2649207C Magnetic nanoparticles compositions and uses thereof
06/03/2014CA2635015C Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
06/03/2014CA2590110C Kinase modulators and method of use
06/03/2014CA2586701C Lna oligonucleotides and the treatment of cancer
06/03/2014CA2486716C Compositions and their uses for alleviating pain
06/03/2014CA2443995C Endothelial cell expression patterns
06/03/2014CA2434490C Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
06/03/2014CA2361334C Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
05/2014
05/30/2014WO2014082085A1 Use of itk inhibitors for the treatment of cancer
05/30/2014WO2014082065A1 Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof
05/30/2014WO2014081953A1 Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
05/30/2014WO2014081937A2 Oncolytic poliovirus for human tumors
05/30/2014WO2014081925A1 Glutamase inhibitors and method of use
05/30/2014WO2014081816A1 Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds
05/30/2014WO2014081732A1 Azaindole derivatives as jak3 inhibitors
05/30/2014WO2014081689A1 Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
05/30/2014WO2014081655A1 Tin-1 17m comprising somatostatin receptor binding compounds
05/30/2014WO2014081300A1 Channel protein activatable liposomes
05/30/2014WO2014081299A1 Activatable liposomes
05/30/2014WO2014081157A1 Novel tetrahydropyridinol derivative compound, and pharmaceutical composition comprising same as active ingredient for preventing or treating cancer
05/30/2014WO2014081025A1 Novel crystal form of 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-n-(2-hydroxyethoxy)-5-(3-oxo-[1,2]oxazinan-2-ylmethyl)benzamide
05/30/2014WO2014080997A1 Anti-midkine aptamer and applications thereof
05/30/2014WO2014080730A1 Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof
05/30/2014WO2014080251A1 Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
05/30/2014WO2014079977A1 Pharmaceutical formulations
05/30/2014WO2014079943A1 Cd44v6-derived peptides for treating metastasizing cancers
05/30/2014WO2014079940A1 Cd44v6-derived peptides for treating pancreatic cancer
05/30/2014WO2014079931A1 Cd44v6-derived peptides for treating breast cancers
05/30/2014WO2014079914A1 Cd44v6-derived pegylated peptides
05/30/2014WO2014079886A1 Anti-ceacam5 antibodies and uses thereof
05/30/2014WO2014079583A1 Chondramide derivatives
05/30/2014WO2014079545A1 Thioether derivatives as protein kinase inhibitors
05/30/2014WO2014079377A1 Antitumor prodrugs with function of p-glycoprotein inhibition
05/30/2014WO2014079364A1 Imidazolone derivatives, pharmaceutical compositions and uses thereof
05/30/2014WO2014079232A1 7-oxo-pyridopyrimidine derivatives, pharmaceutical compositions and uses thereof
05/30/2014WO2014079158A1 Active-targeting, small interference ribonucleic acid delivery vector and preparation method thereof
05/30/2014WO2014079150A1 Compounds and their methods of use
05/30/2014WO2014079136A1 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof
05/30/2014WO2014079070A1 Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof
05/30/2014WO2014079011A1 Heterocyclic compounds for inhibiting glutaminase and their methods of use
05/30/2014WO2014079000A1 Bispecific antibody
05/30/2014WO2014078898A1 Chemotherapy for drug-resistant cancer cells
05/30/2014WO2014078896A1 Complex-formation-modulating agents and uses therefor
05/30/2014WO2014078895A1 Omega-3 analogues
05/30/2014WO2014078889A1 Improved inhibitors of grb7
05/30/2014WO2014059199A8 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
05/30/2014WO2014055972A3 A new chemical entity useful for treating various diseases
05/30/2014WO2014031487A8 Bivalent inhibitors of iap proteins and therapeutic methods using the same
05/30/2014WO2013184912A4 Binding agents that modulate the hippo pathway and uses thereof
05/29/2014US20140148509 Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same
05/29/2014US20140147444 Selective binding agents of osteoprotegerin binding protein
05/28/2014EP2735613A1 TECHNIQUE FOR CLEAVING OUT PART OF poly(A) CHAIN AND/OR 3'-TERMINAL SEQUENCE OF mRNA TO INHIBIT TRANSLATION REACTION
05/28/2014EP2735562A1 Estrogen receptor modulators and uses thereof
05/28/2014EP2735314A1 Improved sugar-coated liposome composition
05/28/2014EP2734530A1 Heterocyclic compounds and uses thereof
05/28/2014EP2734523A1 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
05/28/2014EP2734522A1 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
05/28/2014EP2734505A1 3-(fluorvinyl)pyrazoles and the use thereof
05/28/2014EP2734504A1 Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
05/28/2014EP2734232A1 Sequential anti - ctla4 and targeted il-2 therapy
05/28/2014EP2734228A1 Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death
1 ... 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 ... 2211